HomepageIPSEY • OTCMKTS
add
Ipsen
Vorige slotkoers
$Â 28,39
Dag-range
$Â 28,04 - $Â 29,19
Jaar-range
$Â 26,97 - $Â 34,06
Beurswaarde
9,04Â mld. EUR
Gem. volume
1,15K
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 875,90Â mln. | 7,93% |
Bedrijfskosten | 557,05Â mln. | 8,31% |
Netto inkomsten | 116,00Â mln. | 18,85% |
Netto winstmarge | 13,24 | 10,06% |
Winst per aandeel | — | — |
EBITDA | 240,85Â mln. | 0,31% |
Effectief belastingtarief | 16,30% | — |
Balans
Totale activa
Totale passiva
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 485,40Â mln. | 17,42% |
Totale activa | 6,55Â mld. | 7,50% |
Totale passiva | 2,50Â mld. | -6,93% |
Totaal aandelenvermogen | 4,05 mld. | — |
Uitstaande aandelen | 82,86 mln. | — |
Koers-boekwaardeverhouding | 0,58 | — |
Rendement op activa | 6,13% | — |
Rendement op kapitaal | 8,85% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 116,00Â mln. | 18,85% |
Operationele kasstroom | 233,00Â mln. | 8,52% |
Kasstroom uit beleggingen | -99,55Â mln. | 79,81% |
Kasstroom uit financiering | -159,10Â mln. | -51,45% |
Nettomutatie in liquide middelen | -26,00Â mln. | 93,10% |
Vrije kasstroom | 15,01Â mln. | -89,78% |
Over
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
CEO
Opgericht
1929
Website
Werknemers
5.325